Asia Pacific Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Cardiovascular disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet, and Injection), Route of Administration (Oral, and Intravenous), End Users (Hospital, Clinic, and Homecare Settings), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Name: Asia Pacific Cardiometabolic Diseases Market
SKU: Pharmaceuticals
Rating: 4.9 (14 reviews)

Market Introduction

The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.

Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the Asia Pacific cardiometabolic diseases market.

The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected those economies in the Asia Pacific region. Countries such as India (31,769,132), Japan (956,407), China (93,289), South Korea (203,926) were adversely affected by the pandemic. The socioeconomics were severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Recently, patients with both hypertension and obesity have been increasing in Japan. These patients are at exceptionally high risk for severe disease in COVID-19 and thus need careful observation and intensive treatment. Comparable to hypertension, the definition of obesity is not constant among studies/countries, which requires consideration. However, it is essential to note that the therapeutic mechanism of CCB against COVID-19 still awaits further investigation and randomized controlled clinical trials.

Market Overview and Dynamics

The Asia Pacific cardiometabolic diseases market is projected to reach US$ 28,953.2 million by 2028 from US$ 21,091.3 million in 2021; it is anticipated to grow at a CAGR of 4.6% from 2021 to 2028. Cardiometabolic diseases (CMDs) are one of the leading causes of death worldwide. These diseases are mainly caused by an unhealthy lifestyle, physical inactivity, smoking, and an unhealthy diet. CMDs include cardiovascular diseases (CVDs), diabetes mellitus, and chronic renal failure. Most cardiovascular diseases can be prevented by addressing behavioural risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. There is a rise in the number of people having one or more CMDs due to increasing smoking, lack of exercise, alcohol consumption, and unhealthy food habits. The increasing prevalence of obesity is giving rise to the patient base suffering from CMDs as well. With this rapid upswing in the prevalence of CMDs, the need for appropriate cardiometabolic disease treatments has skyrocketed, resulting in tremendous growth of the Asia Pacific cardiometabolic diseases market.

Key Market Segments

In terms of type, the cardiovascular disease segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the Asia Pacific cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc., and Kowa Company, Ltd.

Reasons to Buy Report

To understand the Asia Pacific cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
To comprehend the ever-changing market landscape and stay ahead in competition
To efficiently plan merger and acquisition, and partnership deals in the Asia Pacific cardiometabolic diseases market by identifying segments with the most promising probable sales
To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
To obtain market revenue forecast of the Asia Pacific cardiometabolic diseases market based on various segments for the period 2021–2028

ASIA PACIFIC CARDIOMETABOLIC DISEASES MARKET SEGMENTATION

By Type

Cardiovascular disease (CVD)
Type 2 diabetes
Hypertension
Obesity

By Treatment

ACE inhibitors
Diuretics
Glucophage
Others

By Dosage

Tablet
Injection

By Route of Administration

Oral
Intravenous

By End Users

Hospital
Clinic
Homecare settings

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Country

Companies Mentioned

1. Introduction 21

1.1 Scope of the Study. 21

1.2 The Insight Partners Research Report Guidance. 21

1.3 Market Segmentation. 23

1.3.7 Asia Pacific Cardiometabolic Diseases market – By Country. 25

2. Asia Pacific Cardiometabolic Diseases Market – Key Takeaways 26

3. Research Methodology 31

3.1 Coverage. 33

3.2 Secondary Research. 33

3.3 Primary Research. 34

4. Asia Pacific Cardiometabolic Diseases Market – Market Landscape 35

4.1 Overview.. 35

4.2 PEST Analysis. 36

4.3 Expert Opinions. 37

5. Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics 38

5.1 Market Drivers. 38

5.1.1 Increasing Prevalence of Cardiometabolic Diseases. 38

5.1.2 Innovation in Cardiometabolic Diseases Therapeutics. 38

5.2 Market Restraints. 39

5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs) 39

5.3 Market Opportunities. 40

5.3.1 Technological Advancements in CMD Diagnosis. 40

5.4 Future Trends. 40

5.4.1 Personalized Treatment for CMDs. 40

5.5 Impact Analysis. 41

6. Asia Pacific Cardiometabolic Diseases Market – Regional Analysis 42

6.1 Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis. 42

7. Asia Pacific Cardiometabolic Diseases Market Analysis – By Type 44

7.1 Overview.. 44

7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

7.3 Cardiovascular Disease (CVD) 45

7.3.1 Overview.. 45

7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 46

7.4 Hypertension. 47

7.4.1 Overview.. 47

7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 47

7.5 Type 2 Diabetes. 48

7.5.1 Overview.. 48

7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 48

7.6 Obesity. 50

7.6.1 Overview.. 50

7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 50

8. Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment 52

8.1 Overview.. 52

8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

8.3 ACE inhibitors. 53

8.3.1 Overview.. 53

8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn) 53

8.4 Diuretics. 55

8.4.1 Overview.. 55

8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 55

8.5 Glucophage. 56

8.5.1 Overview.. 56

8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 56

8.6 Others. 57

8.6.1 Overview.. 57

8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 57

9. Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage 58

9.1 Overview.. 58

9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

9.3 Tablet 59

9.3.1 Overview.. 59

9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 59

9.4 Injection. 60

9.4.1 Overview.. 60

9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 60

10. Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration 61

10.1 Overview.. 61

10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

10.3 Oral 62

10.3.1 Overview.. 62

10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn) 62

10.4 Intravenous. 64

10.4.1 Overview.. 64

10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn) 64

11. Asia Pacific Cardiometabolic Diseases Market Analysis – By End User 66

11.1 Overview.. 66

11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

11.3 Clinic. 67

11.3.1 Overview.. 67

11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn) 67

11.4 Hospital 68

11.4.1 Overview.. 68

11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn) 68

11.5 Homecare Settings. 70

11.5.1 Overview.. 70

11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn) 70

12. Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel 72

12.1 Overview.. 72

12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

12.3 Hospital Pharmacy. 73

12.3.1 Overview.. 73

12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 73

12.4 Retail Pharmacy. 74

12.4.1 Overview.. 74

12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 74

12.5 Online Pharmacy. 76

12.5.1 Overview.. 76

12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 76

13. Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis 78

13.1 Asia Pacific: Cardiometabolic Diseases Market 78

13.1.1 Overview.. 78

13.1.2 Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 80

13.1.3 Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

13.1.4 Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

13.1.5 Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

13.1.6 Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

13.1.7 Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

13.1.8 Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

13.1.9 Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

13.1.9.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 85

13.1.9.1.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

13.1.15.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.15.1.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

13.1.21.1 India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million) 95

13.1.21.1.1 India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

13.1.27.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.27.1.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

13.1.33.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.33.1.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

13.1.39.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.39.1.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

14. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 115

14.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic. 115

15. Asia Pacific Cardiometabolic Diseases Market – Industry Landscape 117

15.1 Overview.. 117

15.2 Growth Strategies in the Cardiometabolic Diseases Market (%) 118

15.3 Organic Developments. 119

15.3.1 Overview.. 119

15.4 Inorganic Developments. 122

15.4.1 Overview.. 122

16. Company Profiles 124

16.1 Eli Lilly and Company. 124

16.1.1 Key Facts. 124

16.1.2 Business Description. 124

16.1.3 Products and Services. 125

16.1.4 Financial Overview.. 127

16.1.5 SWOT Analysis. 130

16.1.6 Key Developments. 131

16.2 Bayer AG.. 134

16.2.1 Key Facts. 134

16.2.2 Business Description. 134

16.2.3 Products and Services. 135

16.2.4 Financial Overview.. 135

16.2.5 SWOT Analysis. 138

16.2.6 Key Developments. 139

16.3 Novartis AG.. 141

16.3.1 Key Facts. 141

16.3.2 Business Description. 141

16.3.3 Products and Services. 142

16.3.4 Financial Overview.. 143

16.3.5 SWOT Analysis. 146

16.3.6 Key Developments. 147

16.4 Boehringer Ingelheim International GmbH.. 148

16.4.1 Key Facts. 148

16.4.2 Business Description. 148

16.4.3 Products and Services. 149

16.4.4 Financial Overview.. 150

16.4.5 SWOT Analysis. 154

16.4.6 Key Developments. 155

16.5 Novo Nordisk A/S. 157

16.5.1 Key Facts. 157

16.5.2 Business Description. 157

16.5.3 Products and Services. 158

16.5.4 Financial Overview.. 159

16.5.5 SWOT Analysis. 162

16.5.6 Key Developments. 163

16.6 AstraZeneca. 165

16.6.1 Key Facts. 165

16.6.2 Business Description. 165

16.6.3 Products and Services. 166

16.6.4 Financial Overview.. 167

16.6.5 SWOT Analysis. 170

16.6.6 Key Developments. 171

16.7 Cardax, Inc. 173

16.7.1 Key Facts. 173

16.7.2 Business Description. 173

16.7.3 Products and Services. 174

16.7.4 Financial Overview.. 174

16.7.5 SWOT Analysis. 177

16.7.6 Key Developments. 177

16.8 Kowa Company, Ltd. 178

16.8.1 Key Facts. 178

16.8.2 Business Description. 178

16.8.3 Products and Services. 179

16.8.4 Financial Overview.. 179

16.8.5 SWOT Analysis. 180

16.8.6 Key Developments. 181

17. Appendix 182

17.1 About The Insight Partners. 182

17.2 Glossary of Terms. 183

LIST OF TABLES

Table 1. Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

Table 2. Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

Table 3. Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

Table 4. Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

Table 5. Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

Table 6. Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

Table 7. China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

Table 8. China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

Table 9. China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

Table 10. China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

Table 11. China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

Table 12. China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

Table 13. Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

Table 14. Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

Table 15. Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

Table 16. Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

Table 17. Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

Table 18. Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

Table 19. India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

Table 20. India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

Table 21. India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

Table 22. India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

Table 23. India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

Table 24. India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

Table 25. South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

Table 26. South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

Table 27. South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

Table 28. South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

Table 29. South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

Table 30. South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

Table 31. Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

Table 32. Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

Table 33. Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

Table 34. Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

Table 35. Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

Table 36. Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

Table 37. Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

Table 38. Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

Table 39. Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

Table 40. Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

Table 41. Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

Table 42. Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

Table 43. Organic Developments in the Cardiometabolic Diseases Market 119

Table 44. Inorganic Developments in the Cardiometabolic Diseases Market 123

Table 45. Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market 183

LIST OF FIGURES

Figure 1. Asia Pacific Cardiometabolic Diseases Market Segmentation. 23

Figure 2. Asia Pacific Cardiometabolic Diseases Market Overview.. 26

Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market 27

Figure 4. Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million) 28

Figure 5. Asia Pacific Cardiometabolic Diseases Market, Industry Landscape. 29

Figure 6. Asia Pacific PEST Analysis. 36

Figure 7. Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints. 41

Figure 8. Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028. 43

Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 46

Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 47

Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 49

Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 51

Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 54

Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 55

Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 56

Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 57

Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 59

Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 60

Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn) 63

Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn) 65

Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn) 67

Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn) 69

Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn) 71

Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 73

Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 75

Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 77

Figure 33. Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million) 79

Figure 34. Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million) 80

Figure 35. Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

Figure 36. China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

Figure 37. Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 91

Figure 38. India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

Figure 39. South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 101

Figure 40. Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 106

Figure 41. Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 111

Figure 42. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 116

Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%) 118

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an..	May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec..	May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000